- Home
- RNAC vs DSGN Comparison
RNAC vs DSGN Comparison
Compare RNAC & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAC
- DSGN
- Stock Information
- Founded
- RNAC 2007
- DSGN 2017
- Country
- RNAC United States
- DSGN United States
- Employees
- RNAC N/A
- DSGN N/A
- Industry
- RNAC Biotechnology: Pharmaceutical Preparations
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- RNAC Health Care
- DSGN Health Care
- Exchange
- RNAC Nasdaq
- DSGN Nasdaq
- Market Cap
- RNAC 264.7M
- DSGN 224.8M
- IPO Year
- RNAC 2016
- DSGN 2021
- Fundamental
- Price
- RNAC $10.00
- DSGN $4.04
- Analyst Decision
- RNAC Strong Buy
- DSGN Hold
- Analyst Count
- RNAC 7
- DSGN 1
- Target Price
- RNAC $41.00
- DSGN $4.00
- AVG Volume (30 Days)
- RNAC 76.4K
- DSGN 91.9K
- Earning Date
- RNAC 05-08-2025
- DSGN 05-07-2025
- Dividend Yield
- RNAC N/A
- DSGN N/A
- EPS Growth
- RNAC N/A
- DSGN N/A
- EPS
- RNAC N/A
- DSGN N/A
- Revenue
- RNAC $34,173,000.00
- DSGN N/A
- Revenue This Year
- RNAC N/A
- DSGN N/A
- Revenue Next Year
- RNAC N/A
- DSGN N/A
- P/E Ratio
- RNAC N/A
- DSGN N/A
- Revenue Growth
- RNAC 31.91
- DSGN N/A
- 52 Week Low
- RNAC $8.46
- DSGN $2.60
- 52 Week High
- RNAC $41.87
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- RNAC 43.07
- DSGN 53.86
- Support Level
- RNAC $8.46
- DSGN $3.67
- Resistance Level
- RNAC $10.10
- DSGN $4.13
- Average True Range (ATR)
- RNAC 0.60
- DSGN 0.30
- MACD
- RNAC 0.07
- DSGN 0.05
- Stochastic Oscillator
- RNAC 54.91
- DSGN 85.78
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.